Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 26;118(5):1218–1231. doi: 10.1093/cvr/cvab100

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Mechanism of action of Lp(a)-lowering siRNA therapy, and potential clinical benefits. GalNAc–siRNA drugs lower circulating Lp(a) concentrations via the mechanisms described in more detail in Figure 2. Evidence from observational and genetic epidemiological studies supports a role for Lp(a) lowering as a means of reducing the risk of several types of cardiovascular disease, including atherosclerotic in the coronary and peripheral circulations, valvular disease and heart failure. siRNA, small interfering RNA; ASGPR, asialoglycoprotein receptor; LPA, apolipoprotein(a) gene; Lp(a), lipoprotein(a).